Azitra, Inc. Announces Full Year 2025 Financial Results and Provides Business Updates

Branford, Conn. – February 27, 2026 – Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on innovative therapies for precision dermatology, today released its audited financial results for the full year ended December 31, 2025, and provided an update on its recent business progress.

Key Highlights from FY2025 and Recent Business Developments

• ATR-01 Program Progress: Azitra advanced its ATR-01 clinical program, targeting ichthyosis vulgaris, a chronic skin disorder. This is noteworthy as advances in rare skin disease treatment could drive significant market interest.
• Promising Phase 1b Trial Data for ATR12: The company reported encouraging safety data from its Phase 1b trial of ATR12 in patients with Netherton Syndrome. Positive clinical data in rare dermatological conditions is a potential catalyst for future valuation increases, particularly if efficacy is demonstrated in subsequent trials.
• Successful Capital Raising: Azitra completed \$8.5 million in financing via private placements, follow-on financings, and the use of an equity line of credit. Strengthened cash resources support ongoing R&D and clinical programs, reducing near-term dilution and funding risks.

Financial Results for the Year Ended December 31, 2025

Balance Sheet Highlights:

• Cash and cash equivalents: \$2.07 million (2025), down from \$4.55 million (2024).
• Total assets: \$7.36 million (2025), up from \$7.33 million (2024).
• Total liabilities: \$3.56 million (2025), up from \$1.66 million (2024).
• Stockholders’ equity: \$3.80 million (2025), down from \$5.70 million (2024).

Key Insights and Potential Share Price Catalysts

• Clinical Pipeline Advances: The progression of ATR-01 and ATR12 in rare dermatological diseases could be transformative for Azitra. Any future positive clinical data, regulatory milestones, or partnerships may substantially increase investor interest and share value.
• Funding and Liquidity: The \$8.5 million raised in 2025 provides the company with runway to execute on its clinical programs. However, declining cash balances highlight a need for continued funding, which could lead to further dilution if additional capital is raised in the future.
• Net Loss Narrowing: The significant reduction in net loss (from \$10.99 million to \$8.97 million) and the substantial increase in shares outstanding (reducing per-share losses) may be seen as positive developments, although the company remains pre-revenue with ongoing operating losses.
• Share Dilution: The jump in weighted average shares outstanding from 571,162 to 4,873,552 reflects significant dilution, likely due to financing activities. Shareholders should be aware of this when considering the impact on future EPS and ownership percentages.

Other Notable Information

• Azitra remains an emerging growth company as defined by SEC rules, and has not elected out of extended accounting transition periods.
• All information in the results is unaudited and provided for informational purposes only; refer to attached exhibits for complete details.

Disclaimer: This article is for informational purposes only. It does not constitute investment advice or recommendations. Investors should refer to Azitra, Inc.’s official filings and consult their financial advisors before making any investment decisions. Past performance is not indicative of future results. The company remains pre-revenue and is subject to substantial clinical, regulatory, and financial risks.

View Azitra, Inc. Historical chart here